A pilot single arm observational study of sofosbuvir/ledipasvir (200 + 45 mg) in 6- to 12- year old children.

M H F El-ShabrawiNaglaa M KamalH R El-KhayatEnas M KamalM M A H AbdElgawadNaglaa M. Kamal

Published in: Alimentary pharmacology & therapeutics (2018)

This pilot study demonstrated that the fixed dose sofosbuvir/ledipasvir combination could be safe and effective treatment in children 6- to 12- years with chronic hepatitis C genotype 4 infection. Our pilot results might encourage larger and multicentre studies in this age group.

Keyphrases

hepatitis c virus
study protocol
hepatitis c virus infection
young adults
clinical trial
randomized controlled trial
cross sectional
replacement therapy